Huons Meditech said it participated in the Florida International Medical Expo (FIME) 2024, the largest medical device exhibition in the U.S., held in Florida from June 19-21.
At the event, Huons Meditech unveiled the ASADAL-M1 lithotripter, designed for the fragmentation of kidney stones, and the Huen Single endoscope washer/disinfector in the CSSD segment. In the aesthetic category, the company promoted the DermaShine Pro, a mesotherapy injector utilizing negative pressure.
The ASADAL-M1, certified by the U.S. FDA and the European Medical Device Regulation (CE), employs electro-magnetic extracorporeal shockwave (ESWL) technology to ensure safe and efficient lithotripsy. The non-invasive ESWL procedure, in contrast to traditional surgical stone removal, boasts a quick procedure time and allows for same-day treatment and discharge.
The Huen Single is an automatic endoscope washer/disinfector using a single-use peracetic acid (PAA) disinfectant solution, Sco-Single. It inhibits biofilm formation on both internal and external surfaces of endoscopes and sterilizes all pathogenic microorganisms, including spores, within five minutes. Unlike many endoscope disinfectors that reuse disinfectant solutions, increasing the risk of cross-contamination, the Huen Single uses a single-use disinfectant, eliminating the risk. It also features Clean-in-Place (CIP) functionality and a photocatalytic filter that purifies peracetic acid gases and odors, enhancing device durability and user safety, which attracted high interest from attendees.
The DermaShine Pro, the latest model in the highly successful DermaShine series, features an upgraded pressure-sensing injection system that allows for precise drug infusion and speed settings. Compatible with various syringes (32G, 34G, and 9-pin sterile needles), the device is expected for U.S FDA approval by the second half of next year, leading to numerous inquiries from attendees.
Lee Jin-suk, CEO of Huons Meditech, said the company was strengthening partnerships to expand into global markets through participation in major exhibitions,.
"We will continue to introduce our innovative medical devices, developed with proprietary technology, at exhibitions to increase buyer interest and strive to establish ourselves as a leading global medical device company."
Related articles
- Huons Meditech showcases flagship devices at Hospitalar 2024 in Brazil
- Huons Meditech names Lee Jin-suk as new CEO
- Huons Meditech showcases lithotripter at the American Urological Association meeting
- Huons Meditech to import Canadian device for prostate cancer treatment
- Huonslab registers patent for recombinant human hyaluronidase technology
- Huonslab scores IND nod for clinical trial of recombinant human hyaluronidase
- Huons Global marks record-high Q2 sales of ₩209 billion
- Huons’ oral peptide picked as national development project to fight obesity, diabetes
- Huons names VP Park to head new growth R&D
- Huons Meditech expands global reach by showcasing innovative urology device at SIU 2024 in India
- Huons Meditech surpasses 20,000 units sold in Dermashine product line
